Abstracts by keywords: exenatide
Insulin glargine and exenatide in type 2 diabetes: A cost comparison in combination with oral antidiabetics
This study examined the costs of a combination therapy of exenatide (EXE) and an oral antidiabetic drug (OAD) versus basal-supported oral therapy (BOT) with insulin glargine (GLA) in antihyperglycemic treatment in type 2 diabetics in Germany based on healthcare data . A historical cohort study was conducted using the representative IMS® Disease Analyzer database. Type 2 diabetics who started BOT with GLA or combination therapy with EXE and OAD between 1/2007 and 12/2008 were included.